By Marc Hurlbert, Ph.D. | MRA Chief Executive Officer
The Melanoma Research Alliance (MRA) and our collaborators at the Veterans Administration (VA) Hospitals in Boston and Providence, and at Massachusetts General Hospital (MGH), have finalized our veteran and civilian cohorts. Our cohorts of patients include 1831 acral melanoma, 603 mucosal melanoma, and 2380 uveal melanoma cases. We have confirmed prior known risk factors for acral melanoma, and identified a few novel findings around ‘normal weight/normal BMI’ being at reduced risk. This is suggestive that acral melanoma on the foot may be associated with weight-bearing regions of the foot. This preliminary data is being further refined. The team has also finished our first analysis of risk among uveal melanoma patients in the civilian cohort. Over the next 90 days we will complete the acral, uveal, and mucosal clinical and sociological risk factor analysis, and initiate our analysis of possible inherited gene/genetic risk factors. We aim to complete this project by Fall 2025.
Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.
Support this important cause by creating a personalized fundraising page.
Start a Fundraiser
